- Home
- BGH vs FENC Comparison
BGH vs FENC Comparison
Compare BGH & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGH | FENC |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.7M | 230.8M |
| IPO Year | 2011 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BGH | FENC |
|---|---|---|
| Price | $14.00 | $11.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 88.3K | ★ 287.4K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $1,055.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.19 | $5.65 |
| 52 Week High | $16.90 | $10.59 |
Technical Indicators
Market Signals| Indicator | BGH | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 75.99 |
| Support Level | $13.82 | $7.40 |
| Resistance Level | $13.96 | N/A |
| Average True Range (ATR) | 0.15 | 0.51 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 43.26 | 98.04 |
Price Performance
Historical ComparisonAbout BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation. The Fund seeks capital appreciation as a secondary investment objective when consistent with its primary investment objective. Under normal market conditions, the Fund will invest at least 80% of its Managed Assets in bonds, loans and other income-producing instruments that are, at the time of purchase, rated below investment grade.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.